- ClinicalTrials.gov ID: NCT03746483
- Recruiting participants (Starts Jan. 1, 2019)
- Not accepting healthy volunteers
- UTSW Principal Investigator: MEGHANA NITIN SATHE
summary
The primary objectives of this study is to assess the safety and efficacy of MS1819 in enteric capsules vs porcine pancreatic enzyme replacement therapy (PERT) in patients with exocrine pancreatic insufficiency (EPI) due to cystic fibrosis (CF)
objective
The primary objectives of this study are to assess the safety and efficacy of MS1819-SD vs porcine pancreatic enzyme replacement therapy (PeRT) in patients with exocrine pancreatic insufficiency (ePi) due to cystic fibrosis (CF).